| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2006-08-13 22:15:19 UTC |
|---|
| Update Date | 2022-03-07 02:49:21 UTC |
|---|
| HMDB ID | HMDB0004611 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | 7a-Hydroxydehydroepiandrosterone |
|---|
| Description | 7a-Hydroxydehydroepiandrosterone is a major metabolite of dehydroepiandrosterone (DHEA), which is is 7alpha-hydroxylated by the cytochrome P450 7B1 (EC 1.14.13.100, 25-hydroxycholesterol 7alpha-hydroxylase, CYP7B1) in the human brain and liver microsomes. Exposure to the proinflammatory cytokines TNFalpha, IL-1alpha, IL-1beta, and IL-17 increases CYP7B activity in synovial tissue. Increased CYP7B activity leads to higher levels of the DHEA metabolite 7alpha-OH-DHEA in synovial fluid, which may contribute to the maintenance of the chronic inflammation observed in rheumatoid arthritis patients. The glucocorticoid dhydrocorticosterone inhibits the conversion of DHEA to 7a-Hydroxydehydroepiandrosterone. The total levels of 7a-Hydroxydehydroepiandrosterone are increased in serum of patients with Alzheimer's disease. (PMID: 17467270 , 15751070 , 12667489 , 9520908 ). |
|---|
| Structure | [H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@H](O)C=C2C[C@@H](O)CC[C@]12C InChI=1S/C19H28O3/c1-18-7-5-12(20)9-11(18)10-15(21)17-13-3-4-16(22)19(13,2)8-6-14(17)18/h10,12-15,17,20-21H,3-9H2,1-2H3/t12-,13-,14-,15+,17-,18-,19-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (3beta,7alpha)-3,7-Dihydroxyandrost-5-en-17-one | ChEBI | | 3beta,7alpha-Dihydroxy-5-androstene-17-one | ChEBI | | 3beta,7alpha-Dihydroxyandrost-5-en-17-one | ChEBI | | 7alpha-Hydroxy-dhea | ChEBI | | 7alpha-OH-DHEA | ChEBI | | (3b,7a)-3,7-Dihydroxyandrost-5-en-17-one | Generator | | (3Β,7α)-3,7-dihydroxyandrost-5-en-17-one | Generator | | 3b,7a-Dihydroxy-5-androstene-17-one | Generator | | 3Β,7α-dihydroxy-5-androstene-17-one | Generator | | 3b,7a-Dihydroxyandrost-5-en-17-one | Generator | | 3Β,7α-dihydroxyandrost-5-en-17-one | Generator | | 7a-Hydroxy-dhea | Generator | | 7Α-hydroxy-dhea | Generator | | 7a-OH-DHEA | Generator | | 7Α-OH-dhea | Generator | | 7-Hydroxydehydroepiandrosterone | MeSH | | 7beta-Hydroxydehydroepiandrosterone | MeSH | | 7-Hydroxydehydroepiandrosterone, (3beta)-isomer | MeSH | | 7beta-OH-DHEA | MeSH | | 7 alpha-Hydroxydehydroepiandrosterone | MeSH | | 7-Hydroxydehydroepiandrosterone, (3beta,7beta)-isomer | MeSH | | (-)-7a-Hydroxydehydroepiandrosterone | HMDB | | (3b,7a)-3,7-Dihydroxy-androst-5-en-17-one | HMDB | | 3b,7a-Dihydroxy-5-androsten-17-one | HMDB | | 3b,7a-Dihydroxy-androst-5-en-17-one | HMDB | | 7-a-OH-DHEA | HMDB | | 7-alpha-OH-DHEA | HMDB | | 7a-Hydroxydehydroisoandrosterone | HMDB |
|
|---|
| Chemical Formula | C19H28O3 |
|---|
| Average Molecular Weight | 304.4238 |
|---|
| Monoisotopic Molecular Weight | 304.203844762 |
|---|
| IUPAC Name | (1S,2R,5S,9S,10R,11S,15S)-5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-7-en-14-one |
|---|
| Traditional Name | 7β-oh-dhea |
|---|
| CAS Registry Number | 53-00-9 |
|---|
| SMILES | [H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@H](O)C=C2C[C@@H](O)CC[C@]12C |
|---|
| InChI Identifier | InChI=1S/C19H28O3/c1-18-7-5-12(20)9-11(18)10-15(21)17-13-3-4-16(22)19(13,2)8-6-14(17)18/h10,12-15,17,20-21H,3-9H2,1-2H3/t12-,13-,14-,15+,17-,18-,19-/m0/s1 |
|---|
| InChI Key | OLPSAOWBSPXZEA-JIEICEMKSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Steroids and steroid derivatives |
|---|
| Sub Class | Androstane steroids |
|---|
| Direct Parent | Androgens and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Androgen-skeleton
- 3-hydroxy-delta-5-steroid
- 3-hydroxysteroid
- 7-hydroxysteroid
- 3-beta-hydroxysteroid
- 3-beta-hydroxy-delta-5-steroid
- Oxosteroid
- 17-oxosteroid
- Hydroxysteroid
- Delta-5-steroid
- Cyclic alcohol
- Secondary alcohol
- Ketone
- Organic oxygen compound
- Organooxygen compound
- Carbonyl group
- Hydrocarbon derivative
- Alcohol
- Organic oxide
- Aliphatic homopolycyclic compound
|
|---|
| Molecular Framework | Aliphatic homopolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 182 - 183 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.07 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.9027 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.35 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2365.0 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 225.9 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 173.7 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 170.9 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 274.9 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 464.7 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 494.9 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 119.0 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 985.7 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 409.0 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1294.7 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 291.7 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 365.3 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 385.3 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 340.0 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 41.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| 7a-Hydroxydehydroepiandrosterone,1TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H]([C@H](O[Si](C)(C)C)C=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CCC2=O | 2735.6 | Semi standard non polar | 33892256 | | 7a-Hydroxydehydroepiandrosterone,1TMS,isomer #2 | C[C@]12CC[C@H]3[C@@H]([C@H](O)C=C4C[C@@H](O[Si](C)(C)C)CC[C@@]43C)[C@@H]1CCC2=O | 2723.8 | Semi standard non polar | 33892256 | | 7a-Hydroxydehydroepiandrosterone,1TMS,isomer #3 | C[C@]12CC[C@H]3[C@@H]([C@H](O)C=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2702.2 | Semi standard non polar | 33892256 | | 7a-Hydroxydehydroepiandrosterone,2TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H]([C@H](O[Si](C)(C)C)C=C4C[C@@H](O[Si](C)(C)C)CC[C@@]43C)[C@@H]1CCC2=O | 2689.5 | Semi standard non polar | 33892256 | | 7a-Hydroxydehydroepiandrosterone,2TMS,isomer #2 | C[C@]12CC[C@H]3[C@@H]([C@H](O[Si](C)(C)C)C=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2731.3 | Semi standard non polar | 33892256 | | 7a-Hydroxydehydroepiandrosterone,2TMS,isomer #3 | C[C@]12CC[C@H]3[C@@H]([C@H](O)C=C4C[C@@H](O[Si](C)(C)C)CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2717.5 | Semi standard non polar | 33892256 | | 7a-Hydroxydehydroepiandrosterone,3TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H]([C@H](O[Si](C)(C)C)C=C4C[C@@H](O[Si](C)(C)C)CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2673.4 | Semi standard non polar | 33892256 | | 7a-Hydroxydehydroepiandrosterone,3TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H]([C@H](O[Si](C)(C)C)C=C4C[C@@H](O[Si](C)(C)C)CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2714.7 | Standard non polar | 33892256 | | 7a-Hydroxydehydroepiandrosterone,3TMS,isomer #1 | C[C@]12CC[C@H]3[C@@H]([C@H](O[Si](C)(C)C)C=C4C[C@@H](O[Si](C)(C)C)CC[C@@]43C)[C@@H]1CC=C2O[Si](C)(C)C | 2967.2 | Standard polar | 33892256 | | 7a-Hydroxydehydroepiandrosterone,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@@H]1C=C2C[C@@H](O)CC[C@]2(C)[C@H]2CC[C@]3(C)C(=O)CC[C@H]3[C@H]12 | 2993.6 | Semi standard non polar | 33892256 | | 7a-Hydroxydehydroepiandrosterone,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@H]1CC[C@@]2(C)C(=C[C@@H](O)[C@H]3[C@@H]4CCC(=O)[C@@]4(C)CC[C@@H]32)C1 | 2993.5 | Semi standard non polar | 33892256 | | 7a-Hydroxydehydroepiandrosterone,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC1=CC[C@H]2[C@@H]3[C@H](O)C=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C | 2998.8 | Semi standard non polar | 33892256 | | 7a-Hydroxydehydroepiandrosterone,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@H]1CC[C@@]2(C)C(=C[C@@H](O[Si](C)(C)C(C)(C)C)[C@H]3[C@@H]4CCC(=O)[C@@]4(C)CC[C@@H]32)C1 | 3211.5 | Semi standard non polar | 33892256 | | 7a-Hydroxydehydroepiandrosterone,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1=CC[C@H]2[C@@H]3[C@H](O[Si](C)(C)C(C)(C)C)C=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C | 3295.9 | Semi standard non polar | 33892256 | | 7a-Hydroxydehydroepiandrosterone,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC1=CC[C@H]2[C@@H]3[C@H](O)C=C4C[C@@H](O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 3252.4 | Semi standard non polar | 33892256 | | 7a-Hydroxydehydroepiandrosterone,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@H]2[C@@H]3[C@H](O[Si](C)(C)C(C)(C)C)C=C4C[C@@H](O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 3397.4 | Semi standard non polar | 33892256 | | 7a-Hydroxydehydroepiandrosterone,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@H]2[C@@H]3[C@H](O[Si](C)(C)C(C)(C)C)C=C4C[C@@H](O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 3107.1 | Standard non polar | 33892256 | | 7a-Hydroxydehydroepiandrosterone,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC1=CC[C@H]2[C@@H]3[C@H](O[Si](C)(C)C(C)(C)C)C=C4C[C@@H](O[Si](C)(C)C(C)(C)C)CC[C@]4(C)[C@H]3CC[C@]12C | 3265.5 | Standard polar | 33892256 |
|
|---|
| General References | - Hennebert O, Chalbot S, Alran S, Morfin R: Dehydroepiandrosterone 7alpha-hydroxylation in human tissues: possible interference with type 1 11beta-hydroxysteroid dehydrogenase-mediated processes. J Steroid Biochem Mol Biol. 2007 May;104(3-5):326-33. Epub 2007 Mar 24. [PubMed:17467270 ]
- Robinzon B, Michael KK, Ripp SL, Winters SJ, Prough RA: Glucocorticoids inhibit interconversion of 7-hydroxy and 7-oxo metabolites of dehydroepiandrosterone: a role for 11beta-hydroxysteroid dehydrogenases? Arch Biochem Biophys. 2003 Apr 15;412(2):251-8. [PubMed:12667489 ]
- Dulos J, van der Vleuten MA, Kavelaars A, Heijnen CJ, Boots AM: CYP7B expression and activity in fibroblast-like synoviocytes from patients with rheumatoid arthritis: regulation by proinflammatory cytokines. Arthritis Rheum. 2005 Mar;52(3):770-8. [PubMed:15751070 ]
- Attal-Khemis S, Dalmeyda V, Michot JL, Roudier M, Morfin R: Increased total 7 alpha-hydroxy-dehydroepiandrosterone in serum of patients with Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 1998 Mar;53(2):B125-32. [PubMed:9520908 ]
|
|---|